(Q46239066)

20 December 2017

title

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma (English)

1 reference

20 December 2017

1 reference

Maria Grazia Fabrini

1

1 reference

20 December 2017

Giovanni Silvano

2

1 reference

20 December 2017

Ivan Lolli

3

1 reference

20 December 2017

Franco Perrone

4

1 reference

20 December 2017

Annarita Marsella

5

1 reference

20 December 2017

Valerio Scotti

6

1 reference

20 December 2017

Luca Cionini

7

1 reference

20 December 2017

publication date

19 November 2008

1 reference

20 December 2017

Journal of Neuro-Oncology

published in

1 reference

20 December 2017

volume

92

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

79-86

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1007/s11060-008-9739-6

exact match

0 references

cites work

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-008-9739-6

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-008-9739-6

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

21 January 2018

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

1 reference

12 December 2020

Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)

1 reference

12 December 2020

Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial

1 reference

12 December 2020

1 reference

12 December 2020

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

1 reference

12 December 2020

The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule

1 reference

12 December 2020

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

12 December 2020

Phase II study of fotemustine in recurrent supratentorial malignant gliomas

1 reference

12 December 2020

Experiences with reoperation on recurrent glioblastoma multiforme.

1 reference

12 December 2020

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

1 reference

12 December 2020

Chemotherapy for brain tumors--a new beginning.

1 reference

12 December 2020

Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas.

1 reference

12 December 2020

Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme

1 reference

12 December 2020

A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.

1 reference

12 December 2020

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

1 reference

12 December 2020

Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme

1 reference

12 December 2020

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

12 December 2020

Salvage temozolomide for prior temozolomide responders

1 reference

12 December 2020

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

1 reference

12 December 2020

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

12 December 2020

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

1 reference

12 December 2020

10.1007/S11060-008-9739-6

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19018476

1 reference

20 December 2017